Moderna Up 109% YTD: Cramer Calls It Investable—Is It a Buy on the Dip?
Jim Cramer’s bullish pivot comes as Moderna stock pulls back from its 109% YTD gain, raising the question: does the dip offer a compelling entry for investors?
Finance entity
All 1 tracked stories fall under one category: markets. Cytomegalovirus (CMV) candidate is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Finance story that mention COVID-19 Vaccine, all published on July 21, 2026.
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: markets. Cytomegalovirus (CMV) candidate is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Finance story that mention COVID-19 Vaccine, all published on July 21, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering COVID-19 Vaccine. Shared-story counts are live from our verified record — not editorial picks.
Jim Cramer’s bullish pivot comes as Moderna stock pulls back from its 109% YTD gain, raising the question: does the dip offer a compelling entry for investors?
COVID-19 Vaccine is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.